

Table 1. Patient Demographic Data and Baseline Characteristics (all treated patients [TC2/3 or IC2/3])				
Variable	Cohort 1: 1L	Cohort 2: 2L	Cohort 3: ≥ 3L	All Patients
No. of patients	139	268	252	659
Median age, years (range)	67 (35-88)	63 (28-83)	64 (38-84)	64 (28-88)
Male, %	51	61	61	59
Race, %				
Asian	9	10	16	12
Black	1	1	2	2
White	88	85	79	84
Other/unknown	2	4	3	3
Ethnicity, %				
Hispanic/Latino	1	2	2	2
Not Hispanic/Latino	91	95	94	94
Not reported/unknown	6	3	4	5
ECOG PS 1, %	57	63	68	64
Current/previous tobacco use, %	84	82	83	83
Nonsquamous histology, %	77	69	72	72
Mutation/tested, No. (%)				
<i>EGFR</i> *†	13/117 (11)	18/219 (8)	14/207 (7)	45/543 (8)
<i>KRAS</i> *	33/100 (33)	50/200 (25)	54/188 (29)	137/488 (28)
<i>ALK</i> *	3/79 (4)	2/151 (1)	4/146 (3)	9/376 (2)
TC3 or IC3 status, %	47	46	46	46

NOTE. TC3 or IC3 = TC ≥ 50% or IC ≥ 10% PD-L1-expressing cells, respectively; TC2/3 or IC2/3 = TC or IC ≥ 5% PD-L1-expressing cells, respectively. Abbreviations: 1L, first line; 2L, second line; 3L, third line; ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; IC, tumor-infiltrating immune cells; PS, performance status; TC, tumor cells.

*Mutational status was not required at enrollment; limited data available.

†Patients were considered *EGFR* mutant for the analysis if their tumor tested positive for at least one of the following mutations: exon 19 deletions or insertions, L858R, exon 20 insertion, G719X, L861Q, or S768I. Three patients with a T790M mutation were not included in this analysis; two of these patients also had an exon 19 deletion. On the basis of a data cutoff of December 1, 2015.

Table 1. Patient Demographic Data and Baseline Characteristics (all treated patients [TC2/3 or IC2/3])